INMB (INmune Bio Inc.) stock: $1.13, $35.0M market cap, $16.3M cash, $18.7M EV, $45.7M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
Our Strategy Company Overview INmune Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction are primary drivers of pathology.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Great Ormond Street Hospital NHS Foundation Trust (exclusive commercial license to MissionEB clinical trial data, February 2025; up to £6M milestone on first FDA/EMA/MHRA marketing authorization); Anthony Nolan (material transfer and license for umbilical cord supply; processing fees and royalties)
Status note Pivotal MissionEB study completed; company transitioning toward regulatory submission and commercialization. Rare Pediatric Disease and Orphan Drug Designation requests submitted; PRV-eligible if FDA approval on or before September 30, 2029.
Partnerships Xencor (exclusive worldwide royalty-bearing license to XPro protein technology targeting soluble TNF; 5% royalty on net sales)
Indications
Alzheimer's disease(Phase 2)
Status note Phase 2 AD-02/MINDFuL topline reported June 2025. Company has halted immediate plans to develop XPro for Alzheimer's or other indications and is seeking a partner to continue development; end-of-Phase-2 FDA meeting January 2026 aligned on a proposed integrated Phase 2b/3 strategy in early AD.
Status note NK cell-priming platform. A U.S. Phase I/II trial in metastatic castration-resistant prostate cancer was terminated; another trial completed enrollment in Q4 2025.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.